Phase 3
Completed N=27
Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors
Hemophilia A With Inhibitors · Hemophilia B With Inhibitors
Source: ClinicalTrials.gov NCT02020369 ↗
Enrolled (actual)
27
Serious AEs
2.0%
Results posted
Jun 2017
Primary outcomePrimary: Proportion of Successfully Treated Mild/Moderate Bleeding Episodes — .849; .932 Proportion of Success of BEs
◆ Published Evidence
Not yet cited
0citations
Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials.
Summary
The purpose of the study is to assess the safety, efficacy and pharmacokinetics of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
Linked Publications (2)
-
Treatment of severe bleeds with eptacog beta in hemophilia A or B with inhibitors: a post hoc analysis of the PERSEPT 1 and 2 trials.
-
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Successfully Treated Mild/Moderate Bleeding Episodes |
.849; .932 | — |
| SECONDARY Proportion of Mild/Moderate Bleeding Episodes With Patient (Pt)-Reported "Good" or "Excellent" Responses at 12 Hours |
0.857; 0.937 | — |
| SECONDARY Time to Assessment of a "Good" or "Excellent" Response of Mild/Moderate Bleeding Episodes by the Patient |
5.98; 3.00 | — |
| SECONDARY Number of Administrations of Study Drug Per Mild/Moderate Bleeding Episode |
2.5; 1.4 | — |
| SECONDARY Total Amount of Study Drug Administered Per Mild/Moderate Bleeding Episode |
187.868; 252.963 | — |
Eligibility Criteria
Inclusion Criteria
- be male with a diagnosis of congenital hemophilia A and/or B of any severity
- have one of the following:
- a positive inhibitor test Bethesda Unit (BU) ≥ 5 (as confirmed at screening by the institutional lab), OR
- a BU 200/µl)
- have a known allergy or hypersensitivity to rabbits
- have platelet count 3 times the upper limit of normal) and/or renal impairment (creatinine >2 times the upper limit of normal)
- have a history of arterial and/or venous thromboembolic events (such as myocardial infarction, ischemic strokes, transient ischemic attacks, deep venous thrombosis or pulmonary embolism) within 2 years prior to first dose of study drug, or current New York Heart Association (NYHA) functional classification score of stage II -IV
- have an active malignancy (those with non-melanoma skin cancer are allowed)
- have any life-threatening disease or other disease or condition which, according to the investigator's judgment, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome (e.g., a history of non-responsiveness to bypassing products).
Data sourced from ClinicalTrials.gov (NCT02020369) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.